Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFS-02 for ND1-mutant LHON
CTR20232203Phase 2Terminated
- Sponsor
- Neurophth
- Start
- Aug 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NFS-02 in Leber hereditary optic neuropathy (LHON), sponsored by Neurophth. Primary endpoint: Incidence of adverse events, serious adverse events, and dose-limiting toxicities within 52 weeks. Started Aug 2023; status: terminated.
02
Drugs
NFS-02
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on CTR20232203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232203.